Relypsa to Present at the Cantor Fitzgerald Inaugural Healthcare Conference

REDWOOD CITY, Calif., July 1, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq: RLYP), today announced that John A. Orwin, president and chief executive officer, will present at the Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 at 11:45 a.m. ET.

To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at www.relypsa.com.

About Relypsa, Inc.

Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company's two-part pivotal Phase 3 trial of its lead product candidate, Patiromer for Oral Suspension, for the treatment of hyperkalemia, a potentially life-threatening condition defined as abnormally elevated levels of potassium in the blood, has been completed and the primary and secondary endpoints were met. A New Drug Application for Patiromer for Oral Suspension for the treatment of hyperkalemia was accepted by the U.S. Food and Drug Administration and is currently under review. Relypsa has global royalty-free commercialization rights to Patiromer for Oral Suspension, which has intellectual property protection in the U.S. until at least 2030. More information is available at www.relypsa.com.

CONTACT: Alex Dobbin
         Associate Director, Investor Relations
         650-421-9687
         [email protected]

You May Also Be Interested In

• Buddy Brings Native Ecommerce to Flowhub Dispensaries, Live in 24 Hours
• Best Crypto Presale: AlphaPepe Nears $2.5M as Buyers Race the August 26 Presale Closure Timeline
• Memecoin Launches Today: How MemeToro Uses AI Agents to Build Fair Launch Ecosystems